| Title |
Sigma receptors: biology and therapeutic potential
|
|---|---|
| Published in |
Psychopharmacology, June 2004
|
| DOI | 10.1007/s00213-004-1920-9 |
| Pubmed ID | |
| Authors |
Xavier Guitart, Xavier Codony, Xavier Monroy |
| Abstract |
More than 20 years after the identification of the sigma receptors as a unique binding site in the brain and in the peripheral organs, several questions regarding this receptor are still open. Only one of the subtypes of the receptor has been cloned to date, but the endogenous ligand still remains unknown, and the possible association of the receptor with a conventional second messenger system is controversial. From the very beginning, the sigma receptors were associated with various central nervous system disorders such as schizophrenia or movement disorders. Today, after hundreds of papers dealing with the importance of sigma receptors in brain function, it is widely accepted that sigma receptors represent a new and different avenue in the possible pharmacological treatment of several brain-related disorders. In this review, what is known about the biology of the sigma receptor regarding its putative structure and its distribution in the central nervous system is summarized first. The role of sigma receptors regulating cellular functions and other neurotransmitter systems is also addressed, as well as a short overview of the possible endogenous ligands. Finally, although no specific sigma ligand has reached the market, different pharmacological approaches to the alleviation and treatment of several central nervous system disorders and deficits, including schizophrenia, pain, memory deficits, etc., are discussed, with an overview of different compounds and their potential therapeutic use. |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| Canada | 1 | <1% |
| China | 1 | <1% |
| Denmark | 1 | <1% |
| Spain | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 135 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 28 | 20% |
| Researcher | 27 | 19% |
| Student > Bachelor | 17 | 12% |
| Student > Master | 15 | 10% |
| Student > Doctoral Student | 10 | 7% |
| Other | 22 | 15% |
| Unknown | 24 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 28 | 20% |
| Medicine and Dentistry | 20 | 14% |
| Chemistry | 15 | 10% |
| Neuroscience | 13 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 8% |
| Other | 24 | 17% |
| Unknown | 32 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2023.
All research outputs
#7,451,284
of 22,780,165 outputs
Outputs from Psychopharmacology
#2,098
of 5,343 outputs
Outputs of similar age
#18,676
of 57,652 outputs
Outputs of similar age from Psychopharmacology
#16
of 24 outputs
Altmetric has tracked 22,780,165 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,343 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 57,652 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.